Results 61 to 70 of about 170,525 (342)
Advanced Biology, EarlyView.The review provides a critical up‐to‐date overview of the current landscape of human in vitro models for fatty liver disease, including spheroids, organoids, organ‐on‐a‐chip systems, bioprinted liver constructs and precision‐cut liver slices. Their utility for faithfully modeling different stages of MASLD and MASH are evaluated and their compatibility ...
Sonia Youhanna +6 more
wiley +1 more source
Hepatology, EarlyView., 2022 Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim +12 more
wiley +1 more source
Российский кардиологический журнал, 2023 Aim. To assess the characteristics of ST-segment elevation myocardial infarction (STEMI) in patients with metabolic syndrome (MS) in the presence and absence of metabolic-associated fatty liver disease (MAFLD).Material and methods.
V. A. Tretyakova +5 more
doaj +1 more source
Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease [PDF]
, 2018 OBJECTIVE: To determine the percentage of children with nonalcoholic fatty liver disease (NAFLD) in whom intervention for low-density lipoprotein cholesterol or triglycerides was indicated based on National Heart, Lung, and Blood Institute guidelines.
Adina Alazraki +112 more
core +2 more sources
Gastroenterology, 2015 BACKGROUND & AIMS Nonalcoholic steatohepatitis (NASH) has been predicted to become the leading indication for liver transplantation (LT) in the United States.
R. Wong +6 more
semanticscholar +1 more source
Advanced Functional Materials, EarlyView.A galactose‐modified supramolecular near‐infrared (NIR) glycoprobe, TCF‐FBN@Gal‐BSA, enables targeted delivery to the liver through the asialoglycoprotein receptor (ASGPR) and facilitates liver‐targeting fluorescence visualization of lipid droplets (LDs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) mice.
Han‐Min Wang +12 more
wiley +1 more source
Hepatology, EarlyView., 2022 Physiological activation of myeloid p38 controls macrophage IL‐12 production and crosstalk to the liver by modulating hepatic FGF21, and subsequently, brown adipose tissue thermogenesis during obesity Abstract Obesity features excessive fat accumulation in several body tissues and induces a state of chronic low‐grade inflammation that contributes to ...
María Crespo +14 more
wiley +1 more source
Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. [PDF]
, 2019 The gut microbiome, the multispecies community of microbes that exists in the gastrointestinal tract, encodes several orders of magnitude more functional genes than the human genome. It also plays a pivotal role in human health, in part due to metabolism
Lynch, Susan V +3 more
core +1 more source
Advanced Materials, EarlyView.The lipid droplet inhibitor (LDI), templated with large‐pore mesoporous silica and functionalized with PKCα C1A and lipase, targets lipid degradation in fatty liver. The LDI maintains stable association with lipid droplets, thereby suppressing their formation and expansion.
Seunghee Kim +12 more
wiley +1 more source
Hepatology, EarlyView., 2022 IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu +20 more
wiley +1 more source